gnidimacrin: a daphnane-type orthoester diterpene similar in structure to phorbols; antileukemic; found in Gnidia, Stellera, Pimelea; structure
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Stellera | genus | [no description available] | Thymelaeaceae | A plant family of the order Myrtales, subclass Rosidae, class Magnoliopsida. They are mainly trees and shrubs. Many members contain mucilage and COUMARINS.[MeSH] |
Gnidia | genus | [no description available] | Thymelaeaceae | A plant family of the order Myrtales, subclass Rosidae, class Magnoliopsida. They are mainly trees and shrubs. Many members contain mucilage and COUMARINS.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 3085204 |
CHEMBL ID | 4786738 |
MeSH ID | M0060427 |
Synonym |
---|
60796-70-5 |
gnidimacrin |
[benzoyloxy-trihydroxy-(hydroxymethyl)-isopropenyl-dimethyl-[?]yl]methyl benzoate |
CHEMBL4786738 |
[(1r,2s,4r,5r,6s,7s,9r,10s,11s,12s,13s,14s,15r,22r,23s,25r)-12-benzoyloxy-10,11,22-trihydroxy-9-(hydroxymethyl)-13,15-dimethyl-4-prop-1-en-2-yl-8,24,26,27-tetraoxaheptacyclo[12.10.1.14,23.15,23.01,6.07,9.011,25]heptacosan-2-yl]methyl benzoate |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1718300 | Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay | 2020 | Journal of natural products, 12-24, Volume: 83, Issue:12 | Anti-HIV Tigliane Diterpenoids from |
AID1718299 | Antiviral activity against HIV-1 NL4-3 infected in human MT4 cells assessed as reduction in p24 gag protein expression incubated for 48 hrs by ELISA | 2020 | Journal of natural products, 12-24, Volume: 83, Issue:12 | Anti-HIV Tigliane Diterpenoids from |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (15.38) | 18.7374 |
1990's | 3 (23.08) | 18.2507 |
2000's | 4 (30.77) | 29.6817 |
2010's | 3 (23.08) | 24.3611 |
2020's | 1 (7.69) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (7.69%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (92.31%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |